Skip to main content
SpringerLink
Log in

Myogenic Ptosis

  • Chapter
  • First Online:
Book cover Evaluation and Management of Blepharoptosis

Abstract

Myogenic ptosis may present in children or adults. There is commonly reduced levator function and associated weakness of the extraocular, orbicularis oculi, and facial muscles. In some cases, one may find bulbar, limb, and respiratory muscle weakness, as well as a variety of other associated findings, such as frontal balding and polychromatophilic cataracts in myotonic dystrophy. Myogenic ptosis can frequently be diagnosed via muscle biopsy or genetic testing. Ptosis surgery may be quite effective, although frontalis slings are often ultimately necessary due to the progressive nature of myopathic ptosis in many or most cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 189.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hornblass A, Adachi M, Wolintz A, Smith B. Clinical and ultrastructural correlation in congenital and acquired ptosis. Ophthalmic Surg. 1976;7(1):69–76.

    CAS  PubMed  Google Scholar 

  2. Frueh BR. The mechanistic classification of ptosis. Ophthalmology. 1980;87(10):1019–21.

    Article  CAS  PubMed  Google Scholar 

  3. Heidary G, Engle EC, Hunter DG. Congenital fibrosis of the extraocular muscles. Semin Ophthalmol. 2008;23(1):3–8.

    Article  PubMed  Google Scholar 

  4. Allen CE, Rubin PA. Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES): clinical manifestation and treatment. Int Ophthalmol Clin. 2008;48(2):15–23.

    Article  PubMed  Google Scholar 

  5. De Baere E. Blepharophimosis, ptosis and epicanthus inversus. Gene Reviews. Initial posting 8 July 2004. Last revised 15 Feb 2006. Online at www.ncbi.nlm.nih.gov/bookshelf

  6. Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol. 1958;60(2):280–9.

    Article  CAS  PubMed  Google Scholar 

  7. Berenberg RA, Pellock JM, DiMauro S, Schotland DL, Bonilla E, Eastwood A, et al. Lumping or splitting? “Ophthalmoplegia-plus” or Kearns-Sayre syndrome? Ann Neurol. 1977;1(1):37–54.

    Article  CAS  PubMed  Google Scholar 

  8. Eagle Jr RC, Hedges TR, Yanoff M. The atypical pigmentary retinopathy of Kearns-Sayre syndrome. A light and electron microscopic study. Ophthalmology. 1982;89(12):1433–40.

    Article  PubMed  Google Scholar 

  9. Young TJ, Shah AK, Lee MH, Hayes DL. Kearns-Sayre syndrome: a case report and review of cardiovascular complications. Pacing Clin Electrophysiol. 2005;28(5):454–7.

    Article  PubMed  Google Scholar 

  10. Lauwers MH, Van Lersberghe C, Camu F. Inhalation anaesthesia and the Kearns-Sayre syndrome. Anaesthesia. 1994;49(10):876–8.

    Article  CAS  PubMed  Google Scholar 

  11. Egger J, Wilson J. Mitochondrial inheritance in a mitochondrially mediated disease. N Engl J Med. 1983;309(3):142–6.

    Article  CAS  PubMed  Google Scholar 

  12. Leveille AS, Newell FW. Autosomal dominant Kearns-Sayre syndrome. Ophthalmology. 1980;87(2):99–108.

    Article  CAS  PubMed  Google Scholar 

  13. Ogasahara S, Yorifuji S, Nishikawa Y, Takahashi M, Wada K, Hazama T, et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology. 1985;35(3):372–7.

    Article  CAS  PubMed  Google Scholar 

  14. Thornton C. The myotonic dystrophies. Semin Neurol. 1999;19(1):25–33.

    Article  CAS  PubMed  Google Scholar 

  15. Meola G, Moxley 3rd RT. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol. 2004;251(10):1173–82.

    Article  PubMed  Google Scholar 

  16. Oya Y, Yoshida H, Takeshima M, Toyama J, Shigeto H, Ogawa M, et al. Beneficial effect of eyelid makeup (natural rubber latex) to induce a new fold in the treatment of blepharoptosis in myotonic dystrophy. Rinsho Shinkeigaku. 2000;40(5):483–6.

    CAS  PubMed  Google Scholar 

  17. Codere F, Brais B, Rouleau G, Lafontaine E. Oculopharyngeal muscular dystrophy: what’s new? Orbit. 2001;20(4):259–66.

    Article  PubMed  Google Scholar 

  18. Blumen SC, Korczyn AD, Lavoie H, Medynski S, Chapman J, Asherov A, et al. Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene. Neurology. 2000;55(9):1267–70.

    Article  CAS  PubMed  Google Scholar 

  19. Tome FM, Chateau D, Helbling-Leclerc A, Fardeau M. Morphological changes in muscular fibers in oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1997;7 Suppl 1:S63–9.

    Article  PubMed  Google Scholar 

  20. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O’Donovan DG, et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med. 2005;11(6):672–7.

    Article  CAS  PubMed  Google Scholar 

  21. Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2006;15(1):23–31.

    Article  CAS  PubMed  Google Scholar 

  22. Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM, Simonelig M. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum Mol Genet. 2009;18(10):1849–59.

    Article  CAS  PubMed  Google Scholar 

  23. Verheesen P, de Kluijver A, van Koningsbruggen S, de Brij M, de Haard HJ, van Ommen GJ, et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum Mol Genet. 2006;15(1):105–11.

    Article  CAS  PubMed  Google Scholar 

  24. Molgat YM, Rodrigue D. Correction of blepharoptosis in oculopharyngeal muscular dystrophy: review of 91 cases. Can J Ophthalmol. 1993;28(1):11–4.

    CAS  PubMed  Google Scholar 

  25. De Swart BJ, van der Sluijs BM, Vos AM, Kalf JG, Knuijt S, Cruysberg JR, et al. Ptosis aggravates dysphagia in oculopharyngeal muscular dystrophy. J Neurol Neurosurg Psychiatry. 2006;77(22):266–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Coiffier L, Perie S, Laforet P, Eymard B, St Guily JL. Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy. Otolaryngol Head Neck Surg. 2006;135(2):218–22.

    Article  PubMed  Google Scholar 

  27. Burde RM, Savino PJ, Trobe JD. Eyelid disturbances in clinical decisions in neuro-ophthalmology. 3rd ed. St. Louis: Mosby Publishers; 2002.

    Google Scholar 

  28. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459–67.

    Article  PubMed  Google Scholar 

  29. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am. 2008;22(3):509–26.

    Article  PubMed  Google Scholar 

  30. Marino M, Barbesino G, Pinchera A, Manetti L, Ricciardi R, Rossi B, et al. Increased frequency of euthyroid ophthalmopathy in patients with Graves’ disease associated with myasthenia gravis. Thyroid. 2000;10(9):799–802.

    Article  CAS  PubMed  Google Scholar 

  31. Antonio-Santos AA, Eggenberger ER. Medical treatment options for ocular myasthenia gravis. Curr Opin Ophthalmol. 2008;19(6):468–78.

    Article  PubMed  Google Scholar 

  32. Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthal Plast Reconstr Surg. 2001;17(2):103–10.

    Article  CAS  PubMed  Google Scholar 

  33. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48(1):12–38.

    Article  PubMed  Google Scholar 

  34. Dinges WL, Witherspoon SR, Itani KM, Garg A, Peterson DM. Blepharoptosis and external ophthalmoplegia associated with long-term antiretroviral therapy. Clin Infect Dis. 2008;47(6):845–52.

    Article  PubMed  Google Scholar 

  35. Fraunfelder FW, Richards AB. Diplopia, blepharoptosis and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology. 2008;115(12):2282–5.

    Article  CAS  PubMed  Google Scholar 

  36. Song A, Carter KD, Nerad JA, Boldt C, Folk J. Steroid-induced ptosis: case studies and histopathologic analysis. Eye (Lond). 2008;22(4):491–5.

    Article  CAS  Google Scholar 

  37. Wong VA, Beckingsale PS, Oley CA, Sulivan TJ. Management of myogenic ptosis. Ophthalmology. 2002;109(5):1023–31.

    Article  PubMed  Google Scholar 

  38. Patel SM, Linberg JV, Sivak-Callcott JA, Gunel E. Modified tarsal resection operation for congenital ptosis with fair levator function. Ophthal Plast Reconstr Surg. 2008;24(1):1–6.

    Article  PubMed  Google Scholar 

  39. Esmaeli B, Chung H, Pashby RC. Long-term results of frontalis suspension using irradiated, banked fascia lata. Ophthal Plast Reconstr Surg. 1998;14(3):159–63.

    Article  CAS  PubMed  Google Scholar 

  40. Salvi SM, Currie ZI. Frontalis suspension sling using palmaris longus tendon in chronic progressive external ophthalmoplegia. Ophthal Plast Reconstr Surg. 2009;25(2):140–1.

    Article  PubMed  Google Scholar 

  41. Goldey SH, Baylis HI, Goldberg RA, Shorr N. Frontalis muscle flap advancement for correction of blepharoptosis. Ophthal Plast Reconstr Surg. 2000;16(2):83–93.

    Article  CAS  PubMed  Google Scholar 

  42. Carter SR, Meecham WJ, Seiff SR. Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy. Ophthalmology. 1996;103(4):623–30.

    Article  CAS  PubMed  Google Scholar 

  43. Bagheri A, Aletaha M, Saloor H, Yazdani S. A randomized clinical trial of two methods of fascia lata suspension in congenital ptosis. Ophthal Plast Reconstr Surg. 2007;23(3):217–21.

    Article  PubMed  Google Scholar 

  44. Kersten RC, Bernardini FP, Khouri L, Moin M, Roumeliotis AA, Kulwin DR. Unilateral frontalis sling for the correction of unilateral poor-function ptosis. Ophthal Plast Reconstr Surg. 2005;21(6):412–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Maine Eye Center, Portland, ME, USA

    Natan D. Kahn

Authors
  1. Natan D. Kahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natan D. Kahn .

Editor information

Editors and Affiliations

  1. The Art of Eyes, Private Practice, Skokie, 60076, Illinois, USA

    Adam J. Cohen

  2. Concord, NH, Department of Surgery (Ophthalmology), Concord Eye Care, Hanover, 03755, New Hampshire, USA

    David A. Weinberg

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kahn, N.D., Weinberg, D.A. (2011). Myogenic Ptosis. In: Cohen, A., Weinberg, D. (eds) Evaluation and Management of Blepharoptosis. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92855-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-92855-5_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-92854-8

  • Online ISBN: 978-0-387-92855-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation